The performance of the Xpert Bladder Cancer Monitor Test and voided urinary cytology in the follow-up of urinary bladder tumors

Tomaz Smrkolj1,2, Urska Cegovnik Primozic3, Teja Fabjan3, Sasa Sterpin3, Josko Osredkar3,4

1 Department of Urology, Ljubljana University Medical Centre, Ljubljana, Slovenia
2 Department of Surgery, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
3 Clinical Institute of Clinical Chemistry and Biochemistry, Ljubljana University Medical Centre, Ljubljana, Slovenia
4 Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia

Radiol Oncol 2020

Received 22 September 2020
Accepted 3 November 2020

Correspondence to: Prof. Joško Osredkar, Ph.D., Clinical Institute of Clinical Chemistry and Biochemistry, Ljubljana University Medical Centre, SI-1000 Ljubljana, Slovenia. E-mail: josko.osredkar@kclj.si

Disclosure: The Xpert® Urine Transport Reagent kits and Xpert® Bladder Cancer Cartridges were provided free of charge by Biomedis M.B. d.o.o., Juraničeva ul. 11, Maribor, Slovenia. The costs of the application of the present study at The National Medical Ethics Committee of the Republic of Slovenia were covered by Biomedis M.B. d.o.o., Juraničeva ul. 11, Maribor, Slovenia. No other conflicts of interest are declared.

Background. Cystoscopy in complement with urinary cytology represents the gold standard for the follow-up of patients with urinary bladder tumours. Xpert Bladder Cancer Monitor Test (XBC) is a novel mRNA-based urine test for bladder cancer surveillance. The aim of the study was to evaluate the performance of the XBC and voided urinary cytology (VUC) in the follow-up of bladder tumors.

Patients and methods. The XBC was performed on stabilized voided urine and VUC was performed on urine samples. The results were compared to cystoscopic findings and histopathological results after transurethral resection of the bladder lesion.

Results. For the prediction of malignant histopathological result sensitivity, the specificity and negative predictive value were 76.9%, 97.5% and 93.0% for the XBC and 38.4%, 97.5% and 83.3%, respectively for VUC. For the prediction of suspicious or positive cystoscopic finding sensitivity, the specificity and negative predictive value were 75.0%, 95.2%, and 93.0% respectively for the XBC and 41.7%, 97.6%, and 85.4% for VUC. The sensitivities for papillary urothelial neoplasms of low malignant potential (PUNLMP), low- and high-grade tumours were 0.0%, 66.7% and 100.0% for the XBC and 0.0%, 66.7% and 42.9%, respectively for VUC.

Conclusions. The XBC showed significantly higher overall sensitivity and negative predictive value than VUC and could be used to increase the recommended follow-up cystoscopy time intervals. Complementing the XBC and voided urinary cytology does not improve performance in comparison to the XBC alone.

Key words: cystoscopy; Xpert BC Monitor Test; urinary bladder neoplasm; voided urinary cytology

Introduction

Bladder cancer is the ninth most common cancer worldwide. The estimated age-standardized incidence rate of bladder cancer in Europe in 2012 was 17.7 per 100,000 in men and 3.5 per 100,000 in women.1 Ninety percent of bladder tumours are urothelial carcinomas of which 80% are classified as a superficial disease at presentation2, while the rest invade the muscularis propria of the detrusor.

The gold standard for diagnosing and following up bladder tumours is cystoscopy complemented with voided urinary cytology (VUC), and computer tomography urography (CTU), to exclude urothelial carcinoma of the upper urinary tract.3 Cystoscopy is an invasive and painful procedure with potential short- and long-term complications.
VUC on the other hand is noninvasive, detects urothelial carcinoma in both lower and upper urinary tracts, but its sensitivity for detecting well-differentiated bladder tumours is as low as 16% in contrast to 84% for high-grade tumours, therefore VUC cannot replace cystoscopy. The overall sensitivity of CTU for diagnosing bladder cancer is also insufficient to obviate cystoscopy.

In the past two decades, numerous urinary markers for the detection of bladder tumours have been devised, but despite numerous studies, none of these markers have been accepted for diagnosis or follow-up in routine practice or clinical guidelines. Nuclear matrix protein 22 (NMP22), the bladder tumour antigen stat (BTA) test, BTA TRAK test, Immuno Cyt, and fibroblast growth factor receptor 3 (FGFR 3) are FDA approved and commercially available, while many other biomarkers are still being evaluated.

Xpert BC Monitor Test (XBC) is a novel mRNA-based urine test for bladder cancer surveillance, which measures five target mRNAs encoding the following proteins: tyrosine-protein kinase ABL1, corticotropin-releasing hormone (CRH), insulin growth factor 2 (IGF2), uroplakin 1B (UPK1B), and annexin A10 (ANXA10). Except UPK1B, which is a structural protein found in urothelial cells, these proteins play multiple roles during carcinogenesis and are implicated in cell proliferation, division, differentiation, growth, adhesion and signalling. Overall sensitivity (84%) and negative predictive value (93%) of the XBC were reported to be significantly superior to VUC by Pichler et al., who published the first study on the XBC in 2017.

The exclusion criteria were a history of urinary stone disease, ongoing urinary tract infection, suspicion of upper urinary tract tumour, a presence or history of foreign bodies (stent, nephrostomy tube), an invasive procedure on the urinary tract in the past 2 weeks (3 months in case of transurethral resection (TUR) procedure), intravesical chemotherapy or immunotherapy in the past 3 months and prior systemic chemotherapy or radiotherapy of the pelvis.

A total of 54 patients previously diagnosed with bladder tumours were prospectively enrolled in our study from January 2019 to October 2019.

Detection methods

A single voided urinary specimen was collected before conventional white light cystoscopy during a follow-up visit. The frequency of follow-up cystoscopies was based on the European association of urology (EAU) guidelines.8 The urine specimen was divided to provide samples for the XBC (4.5ml) and voided urinary cytology (minimally 50 ml). Voided urinary cytology was analysed in the cytopathological laboratory of the Institute of Pathology, Faculty of Medicine, Ljubljana, Slovenia, and reported according to the Paris classification system.9 The results were classified as negative, suspicious, or positive. In the analysis, suspicious results and cellular atypia were included in the positive group for the comparison of detection performance.

In addition to urine cytology, we also analysed urine samples with the Xpert BC Monitor test (Cepheid, Sunnyvale, CA, USA), which measured the levels of five target mRNAs (ABL1, CRH, IGF2, UPK1B, ANXA10) using reverse transcriptase polymerase chain reaction (RT-PCR) according to the manufacturer’s protocol. 4.5 ml of collected urine was transferred to the prepared transport medium within 1 hour after collection and thus stabilized. The sample thus prepared is stable for up to 7 days at temperatures between 2°C and 28°C. The urine thus prepared was transferred to a reagent cartridge in the laboratory, which contained all the reagents needed for RT-PCR analysis. Automated processing included filter capture on cells, lysis of cells by sonication, addition of nucleic acid to dry RT-PCR reagents, transfer to a reaction chamber, RT-PCR multiplexing, and detection. Sample adequacy monitoring (ABL1) ensures that the sample contains human cells and human RNA. An ABL1 signal was required for a valid test result. The internal control detects pattern-related inhibition of...
RT-PCR. Control by probe verification (measurement of the fluorescence signal from the probes) is performed prior to sample analysis to monitor bead rehydration, cartridge filling in the cartridge, probe integrity, and toner stability. The Xpert BC Monitor test gives results as “positive” and “negative” based on the results of a linear discriminant analysis (LDA) algorithm that uses the results of the cycle threshold (Ct) of five mRNAs: ABL1, CRH, IGF2, UPK1B and ANXA10 (LDA total calculation). The measurement result is valid if the total LDA value is in the range of -20 to 20. The interpretation of the result is as follows: A “positive” result is obtained if the total LDA is equal to or exceeds the limit value; and ABL1 Ct and total LDA are within the valid range. Not all mRNA targets need be detected for a “positive” test result. A “negative” result is achieved if the LDA Total is below the limit value; and ABL1 Ct is within the valid range. The total LDA of the manufacturer is 0.50 and was determined on the basis of statistical analysis of a large number of samples.

The histopathological report on the transurethral resection of a bladder lesion was done by the histopathological laboratory of the Institute of Pathology, Faculty of Medicine, Ljubljana, Slovenia. The tumour stage was reported according to the TNM classification of malignant tumours, 8th edition, 2017, and the tumour grade was classified according to the 2016 WHO classification. The stage and grade from the histopathological report were used in the analysis of results.

Statistical analysis

Data was analysed using the SPSS software (Statistical Package for the Social Sciences, version 22.0, IBM Corp., Armonk, NY, USA). After testing for normal distribution using the Shapiro Wilk normality test for the variables, differences in the LDA total were compared using the Mann-Whitney U test for benign and malignant histology groups, negative and positive cytology groups, and negative/benign and malignant histology groups respectively (Mann-Whitney U = 73.00, p < 0.000). The median LDA totals were 0.2486 (0.1286–0.3685) and 0.9869 (0.8872–1.0866) in the negative and positive cytology groups respectively (Mann-Whitney U = 12.00, p < 0.000). The Median LDA totals were 0.2467 (0.1357–0.3578) and 0.9273 (0.5904–1.2642) in the negative/benign and malignant histology groups respectively (Mann-Whitney U = 63.00, p < 0.000).

From the ROC curve for the prediction of positive cystoscopic findings, the sensitivity and specificity were 75.0% and 87.5% respectively.
95.2% respectively for the XBC (at optimal 0.4923 cut-off value) and 41.7% and 97.6% for VUC. For the prediction of malignant histological results, the sensitivity and specificity were 76.9% and 97.5% respectively for the XBC (at optimal 0.4923 cut-off value) and 38.4% and 97.5% for VUC. Combining the results of the XBC and VUC did not improve the detection of bladder tumours since VUC did not identify any additional patient that was not already positive in the XBC (Tables 2 and 3).

Stratification for grade sensitivities of the XBC were 0.0%, 66.7%, and 100% for papillary urothelial neoplasms of low malignant potential (PUNLMP), low-grade, and high-grade tumours respectively, while the sensitivities of VUC were 0.0%, 66.7%, and 42.9% for the same grade categories respectively. Stratification for stage sensitivities of the XBC were 100%, 80.0%, 100%, and 100% for carcinoma in situ (CIS), Ta, T1 and T2 tumours, respectively, while the sensitivities of VUC were 50.0%, 40.0%, 50.0% and 100% for the same stage categories respectively. (Table 4).

**Discussion**

In our study, we have evaluated two voided urinary tests: the XBC and VUC in the follow-ups of urinary bladder tumours. Despite the availability of noninvasive urinary tests, cystoscopy complemented with VUC is still the gold standard for the follow-up of urinary bladder tumours.\(^3\) Urinary cytology has low sensitivity for low-grade tumours, which are the most numerous and represent two-thirds of primarily diagnosed bladder tumours.\(^1\) Consequently, the Paris system for reporting urinary cytology was introduced in 2015, instructing cytopathologists to emphasize that a negative result is only valid for high-grade tumours and “suspicious for high grade urothelial carcinoma” and “atypia” categories are still present in this new classification and are reported based on cell characteristics and numbers.\(^1\) Low grade urothelial neoplasia (LGUN) should only be reported if strict criteria are satisfied, but a suggestion of LGUN can

---

**TABLE 1.** Summary of the patients’ demographics and test results numbers

| Gender       | Number of patients | Mean age, years ± SD |
|--------------|--------------------|----------------------|
| All          | 54 [100.0%]        | 70.5 ± 8.8           |
| Male         | 42 [77.8%]         | 70.5 ± 8.7           |
| Female       | 12 [22.2%]         | 70.5 ± 9.6           |

| Noninvasive test / standard invasive diagnostic procedure | Number of patients with TP / FN / TN / FP noninvasive test result |
|----------------------------------------------------------|---------------------------------------------------------------|
| XBC / cystoscopy (LDATC 0.4923)                          | 9 / 3 / 40 / 2                                               |
| XBC / cystoscopy (LDATC 0.5)                             | 8 / 4 / 40 / 2                                               |
| VUC / cystoscopy                                         | 5 / 7 / 41 / 1                                               |
| XBC / histology (LDATC 0.4923)                           | 10 / 3 / 40 / 1                                              |
| XBC / histology (LDATC 0.5)                              | 9 / 4 / 40 / 1                                               |
| VUC / histology                                          | 5 / 8 / 40 / 1                                               |

FN = false negative; FP = false positive; LDATC = linear discriminant analysis total cut-off; SD = standard deviation; TN = true negative; TP = true positive; VUC = voided urinary cytology; XBC = Xpert BC Monitor Test
be made including recommendation to repeat VUC or perform other diagnostic procedures. The cyto-
logical result is affected by the presence of several benign urinary tract conditions and is also depend-
ent on the subjective judgment of the cytopatholo-
gist.15

Depending on the calculated risk of recurrence and progression, 6 to 15 cystoscopy proce-
dures should be performed in the follow-up after the TUR of superficial bladder tumours within 5
years3, which represents invasive instrumentation and a risk for complications for patients, as well as
healthcare and economic burden.

Replacing cystoscopy with a noninvasive, simple, low-cost urine-based test with sufficient per-
formance could modify these follow-up schedules. Such a noninvasive test should have high sensitiv-
ity to detect small recurrent high-grade tumours and avoid the growth and progression to a muscle-
infiltrative disease, which considerably aggravates the patient’s prognosis and quality of life.16

The expression levels of the markers combined in linear discriminate analysis (LDA) are used to
classify samples as negative or positive using a linear model.10 While the LDA total value primarily
serves as a criterion for a positive result of the XBC at the cut-off value suggested by the manufacturer
(0.5), we used the ROC curve and Youden method to optimize the cut-off value to 0.4923, which
improved the sensitivity of XBC for the prediction of positive cystoscopic findings from 66.7% to
75.0%. Considering the LDA total value rather than reporting the results of the XBC as negative/
positive could also be used in longitudinal studies as was shown by Hurle et al., who monitored the
LDA total in the active surveillance of patients with non-muscle-invasive bladder cancer in the Bladder
Cancer Italian Active Surveillance project (BIAS) and reported that an increasing LDA total in a pa-
tient is connected to progressing bladder tumours and could be used to initiate follow-up cystoscopy
instead of enforcing firm scheduling protocols.

They also proposed that in this setting, the LDA
total cut-off would be 0.4.17

Our data shows that sensitivities of the XBC for
predicting positive or suspicious cystoscopic results is considerably higher than for VUC (75.0% vs.
41.2% respectively), and also NPV is improved in comparison to VUC (93.0% vs. 85.4% re-
spectively). The results are comparable to the results of the studies of Van Valenberg et al. and Pichler et
al. (74 % and 84% for sensitivity and 93% and 93% for NPV respectively).7,18 In contrast, the study per-
formed by Elia et al. reported an overall sensitivity of only 46.2% for the XBC, though the vast major-
ity (87%) of the detected bladder tumours in that study were low-grade.19 In our study, none of the
patients with negative XBC had a positive VUC, therefore complementing the results of the XBC

| TABLE 2. Specificity, sensitivity and positive and negative predictive value of noninvasive urinary tests for the prediction of positive cystoscopic findings |
| Test | Sensitivity | Specificity | PPV | NPV |
| XBC, LDATC 0.4923 | 75.0% | 95.2% | 81.8% | 93.0% |
| XBC, LDATC 0.5 | 66.7% | 95.2% | 80.0% | 90.9% |
| VUC | 41.7% | 97.6% | 83.3% | 85.4% |
| XBC, LDATC 0.4923 + VUC | 75.0% | 95.2% | 81.8% | 93.0% |

LDATC = linear discriminant analysis total cut-off; NPV = negative predictive value; PPV = positive predictive value; VUC = voided urinary cytology; XBC = Xpert BC Monitor Test

| TABLE 3. Specificity, sensitivity and positive and negative predictive value of noninvasive urinary tests for the prediction of positive histological results |
| Test | Sensitivity | Specificity | PPV | NPV |
| XBC, LDATC 0.4923 | 76.9% | 97.5% | 90.9% | 93.0% |
| XBC, LDATC 0.5 | 69.2% | 97.5% | 90.0% | 90.0% |
| VUC | 38.4% | 97.5% | 83.3% | 83.3% |
| XBC, LDATC 0.4923 + VUC | 76.9% | 97.5% | 90.9% | 93.0% |

LDATC = linear discriminant analysis total cut-off; NPV = negative predictive value; PPV = positive predictive value; VUC = voided urinary cytology; XBC = Xpert BC Monitor Test

| TABLE 4. Sensitivity of the XBC and voided urinary cytology stratified by tumour stage and grade. Number of cases detected by noninvasive test against number of cases detected by histology analysis is shown in the parenthesis |
| Test / Stage | CIS | Ta | T1 | T2 | Grade | PUNLMP | low grade | high grade |
| XBC, LDATC 0.4923 | 100% (2/2) | 80.0% (4/5) | 100% (2/2) | 100% (1/1) | 0.0% (0/1) | 66.7% (2/3) | 100.0% (7/7) |
| VUC | 50.0% (1/2) | 40.0% (2/5) | 50.0% (1/2) | 100% (1/1) | 0.0% (0/1) | 66.7% (2/3) | 42.9% (3/7) |

LDATC = linear discriminant analysis total cut-off; PUNLMP = papillary urinary neoplasm of low malignant potential; VUC = voided urinary cytology; XBC = Xpert BC Monitor Test
with VUC did not increase sensitivity, specificity, NPV, or PPV, which was also observed in the study by Pichler et al.7

Until more studies on the XBC have been conducted, the range of sensitivities and NPVs cannot be estimated, though our data and already published studies7,18 show that the performance of the XBC is at least comparable to previously studied bladder cancer biomarkers for which studies have reported wide variability in performance. A recent review of bladder cancer biomarkers summarized data from several studies listing the sensitivities of NMP22 in the range of 24% to 81%, of BTA STAT 40% to 72%, of ImmunoCyt 50% to 85%, and of UroVysion 13 to 100%. Probably due to the variability in performance, the authors of this review conclude that current commercially available urinary biomarker-based tests are not sufficiently validated to be widely used in clinical practice.20

Cystoscopy was negative in two of our patients, who were positive in the XBC. One of them had an atypical VUC and a high-grade T1 tumour was confirmed with transurethral resection biopsy (TURB), while in another patient with negative VUC, a tumour was identified at a follow-up cystoscopy after 3 months and a high-grade T1 tumour was confirmed. Both cases suggest that even though cystoscopy is the gold standard for the follow-up of bladder tumours, it should be complemented with a noninvasive urinary test.

The high discrimination power of the XBC between malignant and benign histology groups is a consequence of the highly significant difference between the median LDA total in both groups (0.2486 for benign and 0.9869 for malignant group respectively). Overall sensitivity and NPV for the prediction of a malignant histological result of the XBC (76.9% and 93.0%) greatly outperforms the sensitivity and NPV of VUC (38.4% and 83.3)

Stratification for the tumour grade sensitivity of the XBC was comparable to VUC for PUNLMP (0%) and low-grade tumours (66.7%), though the sensitivity of VUC for high-grade tumours was only 42.6%, while no high-grade tumour was missed by the XBC. Improved performance was also reported by Pichler et al.7, who showed considerably higher sensitivity for low-grade tumours (77% vs. 3%) and high-grade tumour +s (100% vs. 25%) for the XBC and VUC respectively. However, the study published by Elia et al. showed significantly lower sensitivity for low-grade (42%) and high-grade tumours (85.7%).19 When tumours are stratified by grade, the sensitivity in our study is comparable to the study of Van Velenberg et al.18 in categories T1 and T2 (100%) and to the study of Pichler et al.7 in categories CIS (100%) and Ta (80%).

Since high-grade bladder tumours have a stage progression risk of 23% in five years compared to only 4% in low-grade tumours21, the XBC could emerge as a noninvasive test to guide the follow-up schedule for the cystoscopic surveillance of a bladder tumour, as was already proposed by Hurle et al.17 Small, Ta low-grade papillary recurrence, which the XBC could miss, does not present an immediate danger to the patient and early detection is not essential for successful therapy,3,22 while for T1 and T2 high-grade tumours or CIS, the XBC is very likely to be positive.

Even though XBC has high sensitivity and NPV for high grade tumours, the rate of adoption of this and other noninvasive molecular tests to routine clinical practice will also depend on financial resources of the healthcare system. Molecular tests typically cost three to five times the price of VUC (XBC 250 EUR and VUC 40 EUR in Slovenia) and are more expensive than single rigid or even flexible cystoscopic procedure in countries, where fees of healthcare professionals are low to moderate.

The main limitation of the present study is the low number of included patients (54) and therefore the low number of patients with recurrent tumours identified at follow-up (14 patients or 25.9%), which is a consequence of the low recurrence rate and study design. A similar proportion of new recurrence tumours (30.7%) was also observed in a larger study by Pichler et al.7, while the largest published study only reported a 17.9% recurrence rate.18 Furthermore, only 1 patient in the negative histology group had a TUR done, while all the others were counted as negative on the basis of the negative cystoscopic result, possibly missing a small hidden lesion or a lesion in the upper urinary tract.

Conclusions

The XBC showed significantly higher overall sensitivity and negative predictive value than VUC. Its ability to detect intermediate and high-risk superficial tumour recurrences could modify follow-up cystoscopy schedules by increasing the recommended time intervals in patients with a negative XBC. Complementing the XBC and voided urinary cytology does not improve the performance in comparison to the XBC alone.
Acknowledgments

The authors wish to thank Biomedis M.B. d.o.o., Juraničeva ul. 11, Maribor, Slovenia for kindly providing The Xpert® Urinary Transport Reagent kits and Xpert® Bladder Cancer Cartridges, and for covering the costs of application of the present study at The National Medical Ethics Committee of the Republic of Slovenia.

References

1. Antoni S, Ferlay J, Siegel et al. Bladder cancer incidence and mortality: A Global Overview and Recent Trends. *Eur Urol* 2017; 71: 96-108. doi: 10.1016/j.euro.2016.06.010
2. Mariappan P, Fineron P, O’Donnell M, Gailer RM, Watson DJ, Smith G, et al. Combining two grading systems: the clinical validity and inter-observer variability of the 1973 and 2004 WHO bladder cancer classification systems assessed in a UK cohort with 15 years of prospective follow-up. *World J Urol* 2020; [Ahead of print]. doi: 10.1007/s00261-020-03180-5
3. Babjuk M, Burger M, Comprét E, Gontero P, Mostafid AH, Palou J, et al. EAU Guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS) 2020. *European Association of Urology Guidelines 2020 Edition*. Presented at the EAU Annual Congress Amsterdam 2020. Arnhem, The Netherlands: European Association of Urology Guidelines Office, 2020.
4. Iafà FA, Brimo F, Steinberg J, Aprkian AG, Tanguay S, Kassouf W. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. *Urol Oncol* 2015; 33: 66.e25-31. doi: 10.1016/j.urolonc.2014.06.008
5. Trinh TW, Glaizer DI, Sadow CA, Sahni VA, Geller NL, Silverman SG. Bladder cancer diagnosis with CT urography: test characteristics and reasons for false-positive and false-negative results. *Abdom Radiol* 2018; 43: 663-71. doi: 10.1007/s00261-017-1249-6
6. Kim J, Kim WT, Kim WJ. Advances in urinary biomarker discovery in urological research. *Investig Clin Urol* 2020; 61: 58-22. doi: 10.4111/icc.2020.61.51.58.
7. Pichler R, Fritz J, Tulchiner G, Klinglmair G, Soleiman A, Horninger W, et al. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance. *BJU Int* 2018; 121: 29-37. doi: 10.1111/bju.14019
8. Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, et al. EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. *Eur Urol* 2017; 71: 447-61. doi: 10.1016/j.euro.2016.05.041
9. Barkan GA, Wojcik EM, Nayar R, Savic-Prince S, Quek ML, Kurytzy DF, et al. The Paris System for reporting urinary cytology: the quest to develop a standardized terminology. *Adv Anat Pathol* 2016; 23: 193-201. doi: 10.1097/PAP.0000000000000118
10. Wallace E, Higuchi R, Satya M, McCann L, Sin MLY, Bridge JA, et al. Development of a 90-minute integrated noninvasive urinary assay for bladder cancer detection. *J Urol* 2018; 199: 655-62. doi: 10.1016/j.juro.2017.09.141
11. Brierley J, Gospodarowicz MK, Wittekind C. *TNM classification of malignant tumours*. Eighth edition. Chichester, West Sussex, UK; Hoboken, NY: John Wiley & Sons, Inc.; 2017.
12. Moeh H, Reuter VE, Humphrey PA, Ulbright TM. *WHO classification of tumours of the urinary system and male genital organs*. International Agency for Research on Cancer; 2016.
13. Hentschel AE, van Rhijn BWG, Brundl J, Comperat EM, Plass K, Rodriguez O, et al. Papillary urothelial neoplasm of low malignant potential (PUN-LMP): still a meaningful histo-pathological grade category for Ta, non-invasive bladder tumors in 2019? *Urol Oncol* 2020; 38: 440-8. doi: 10.1016/j.urolonc.2019.10.002
14. Testa S, Micali G, Atzori C, Caruso P, Cittadini A, et al. The Paris System for reporting urinary cytology. *Rosenthal DL, Wojcik EM, Kurytzy DF*, editors. New York, NY: Springer Science and Business Media; 2015.
15. Raitanen MP, Aine R, Rintala E, Kallio J, Rajala P, Juusela H, et al. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. *Eur Urol* 2002; 41: 284-9. doi: 10.1030/2838(02)00006-4
16. Stenzl A, Cowan NC, De Santis M, Jakse G, Kurzky MA, Merseburger AS, et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. *Eur Urol* 2009; 55: 815-25. doi: 10.1016/j.eururo.2009.01.002
17. Hurle R, Casale P, Saita A, Colombo P, Elefante GM, Lugezzani G, et al. Clinical performance of Xpert Bladder Cancer (BC) Monitor, a mRNA-based urine test, in active surveillance (AS) patients with recurrent non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Italian Active Surveillance (BIAS) project. *World J Urol* 2020; 38: 2215-20. doi: 10.1007/s00345-019-03002-3
18. Valenberg F, Hijar AM, Wallace E, Bridge JA, Mayne DJ, Besaj S, et al. Prospective validation of an mRNA-based urine test for surveillance of patients with bladder cancer. *Eur Urol* 2019; 75: 853-60. doi: 10.1016/j.euro.2018.11.055
19. Elia DC, Pycha A, Folchini DM, Mian C, Hanspeter E, Schwienbacher C, et al. Diagnostic predictive value of Xpert Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer. *J Clin Pathol* 2019; 72: 140-4. doi: 10.1136/jclinpath-2018-205393
20. Soria F, Droller MJ, Lotan Y, Gontero P, D’Andrea D, Gust KM, et al. An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer. *World J Urol* 2018; 36: 1381-95. doi: 10.1007/s00345-018-2380-x
21. Holmang S, Andius P, Hedelin H, Wester K, Busch C, Johansson SL. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. *J Urol* 2003; 165: 1142-8. PMID: 12157652
22. Goftin OT, Pode D, Lazar A, Katz R, Shapiro A. Watchful waiting policy in recurrent Ta G1 bladder tumors. *Eur Urol* 2006; 49: 303-6. doi: 10.1016/j.euro.2005.12.029